Bayer AG annual return on equity
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bayer AG Return on Equity (ROE) Growth & History (BAYN)
Bayer AG's return on equity was −12.43% for fiscal 2025.
View full Bayer AG company overviewBayer AG annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −12.43% | −4.57 pp |
| 2024 | 2024-12-31 | −7.85% | +0.35 pp |
| 2023 | 2023-12-31 | −8.21% | −19.81 pp |
| 2022 | 2022-12-31 | 11.61% | +8.39 pp |
| 2021 | 2021-12-31 | 3.22% | +30.15 pp |
| 2020 | 2020-12-31 | −26.94% | −35.75 pp |
| 2019 | 2019-12-31 | 8.81% | +4.68 pp |
| 2018 | 2018-12-31 | 4.13% | −19.98 pp |
| 2017 | 2017-12-31 | 24.11% | +6.43 pp |
| 2016 | 2016-12-31 | 17.68% | −0.79 pp |
| 2015 | 2015-12-31 | 18.47% | +1.60 pp |
| 2014 | 2014-12-31 | 16.87% | +0.61 pp |
| 2013 | 2013-12-31 | 16.26% | +3.01 pp |
| 2012 | 2012-12-31 | 13.25% | +0.25 pp |
| 2011 | 2011-12-31 | 13.00% | — |
Bayer AG quarterly return on equity
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.75% | — |
| Q1 2026 | 2026-03-31 | 10.09% | — |
| Q4 2025 | 2025-12-31 | −13.53% | — |
| Q3 2025 | 2025-09-30 | −3.21% | — |
Bayer AG return on equity trends
Over the last five fiscal years, Bayer AG's return on equity increased from −26.94% to −12.43%, a change of +14.51 percentage points. The latest reported quarter, Q2 2026, shows 0.75%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bayer AG source filings ↗Community posts
Bayer wins the first Roundup trial following the Supreme Court ruling
A Missouri jury unanimously ruled for Bayer ($BAYN)’s Monsanto unit in a three-plaintiff Roundup case, rejecting design-defect, fraud and negligence claims. It was the first such trial following the US Supreme Court decision that blocked th ...
Bayer’s Nubeqa cuts risk of metastasis or death in prostate trial
Bayer ($BAYN) disclosed interim Phase 3 results showing that adding Nubeqa to hormone therapy and radiation reduced the risk of metastasis or death by 58% in prostate-cancer patients at high risk of recurrence. Four-year metastasis-free sur ...
